|
1
|
Sonneveld P, Avet-Loiseau H, Lonial S,
Usmani S, Siegel D, Anderson KC, Chng WJ, Moreau P, Attal M, Kyle
RA, et al: Treatment of multiple myeloma with high-risk
cytogenetics: A consensus of the international myeloma working
group. Blood. 127:2955–2962. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Abdi J, Chen G and Chang H: Erratum: Drug
resistance in multiple myeloma: Latest findings and new concepts on
molecular mechanisms. Oncotarget. 6:73642015.PubMed/NCBI
|
|
3
|
Mimura N, Hideshima T and Anderson KC:
Novel therapeutic strategies for multiple myeloma. Exp Hematol.
43:732–741. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kumar SK, Lee JH, Lahuerta JJ, Morgan G,
Richardson PG, Crowley J, Haessler J, Feather J, Hoering A, Moreau
P, et al: Risk of progression and survival in multiple myeloma
relapsing after therapy with IMiDs and bortezomib: A multicenter
international myeloma working group study. Leukemia. 26:149–157.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lionetti M, Biasiolo M, Agnelli L,
Todoerti K, Mosca L, Fabris S, Sales G, Deliliers GL, Bicciato S,
Lombardi L, et al: Identification of microRNA expression patterns
and definition of a microRNA/mRNA regulatory network in distinct
molecular groups of multiple myeloma. Blood. 114:e20–e26. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Calin GA and Croce CM: MicroRNAs and
chromosomal abnormalities in cancer cells. Oncogene. 25:6202–6210.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Calin GA and Croce CM: MicroRNA-cancer
connection: The beginning of a new tale. Cancer Res. 66:7390–7394.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Luo X, Gu J, Zhu R, Feng M, Zhu X, Li Y
and Fei J: Integrative analysis of differential miRNA and
functional study of miR-21 by seed-targeting inhibition in multiple
myeloma cells in response to berberine. BMC Syst Biol. 8:822014.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Seckinger A, Meißner T, Moreaux J, Benes
V, Hillengass J, Castoldi M, Zimmermann J, Ho AD, Jauch A,
Goldschmidt H, et al: miRNAs in multiple myeloma-a survival
relevant complex regulator of gene expression. Oncotarget.
6:39165–39183. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Leotta M, Biamonte L, Raimondi L,
Ronchetti D, Di Martino MT, Botta C, Leone E, Pitari MR, Neri A,
Giordano A, et al: A p53-dependent tumor suppressor network is
induced by selective miR-125a-5p inhibition in multiple myeloma
cells. J Cell Physiol. 229:2106–2116. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chi J, Ballabio E, Chen XH, Kušec R,
Taylor S, Hay D, Tramonti D, Saunders NJ, Littlewood T, Pezzella F,
et al: MicroRNA expression in multiple myeloma is associated with
genetic subtype, isotype and survival. Biol Direct. 6:232011.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Esquela-Kerscher A: The lin-4 microRNA:
The ultimate micromanager. Cell Cycle. 13:1060–1061. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Iorio MV and Croce CM: microRNA
involvement in human cancer. Carcinogenesis. 33:1126–1133. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Garzon R and Marcucci G: Potential of
microRNAs for cancer diagnostics, prognostication and therapy. Curr
Opin Oncol. 24:655–659. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yang R, Fu Y, Zeng Y, Xiang M, Yin Y, Li
L, Xu H, Zhong J and Zeng X: Serum miR-20a is a promising biomarker
for gastric cancer. Biomed Rep. 6:429–434. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Huang G, Chen X, Cai Y, Wang X and Xing C:
miR-20a-directed regulation of BID is associated with the TRAIL
sensitivity in colorectal cancer. Oncol Rep. 37:571–578. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang H, Mao F, Shen T, Luo Q, Ding Z,
Qian L and Huang J: Plasma miR-145, miR-20a, miR-21 and miR-223 as
novel biomarkers for screening early-stage non-small cell lung
cancer. Oncol Lett. 13:669–676. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Xiong Y, Sun F, Dong P, Watari H, Yue J,
Yu MF, Lan CY, Wang Y and Ma ZB: iASPP induces EMT and cisplatin
resistance in human cervical cancer through miR-20a-FBXL5/BTG3
signaling. J Exp Clin Cancer Res. 36:482017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Peng J, Thakur A, Zhang S, Dong Y, Wang X,
Yuan R, Zhang K and Guo X: Expressions of miR-181a and miR-20a in
RPMI8226 cell line and their potential as biomarkers for multiple
myeloma. Tumour Biol. 36:8545–8552. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang W, Corrigan-Cummins M, Barber EA,
Saleh LM, Zingone A, Ghafoor A, Costello R, Zhang Y, Kurlander RJ,
Korde N, et al: Aberrant levels of miRNAs in bone marrow
microenvironment and peripheral blood of myeloma patients and
disease progression. J Mol Diagn. 17:669–678. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Luo M, Tan X, Mu L, Luo Y, Li R, Deng X,
Chen N, Ren M, Li Y, Wang L, et al: MiRNA-21 mediates the
antiangiogenic activity of metformin through targeting PTEN and
SMAD7 expression and PI3K/AKT pathway. Sci Rep. 7:434272017.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liu MH, Yang L, Liu XJ, Nie ZY and Luo JM:
Targeted suppression of miRNA-21 inhibit K562 cells growth through
PTEN-PI3K/AKT signaling pathway. Zhonghua Xue Ye Xue Za Zhi.
37:982–986. 2016.(In Chinese). PubMed/NCBI
|
|
23
|
Yang X, Cheng Y, Li P, Tao J, Deng X,
Zhang X, Gu M, Lu Q and Yin C: A lentiviral sponge for miRNA-21
diminishes aerobic glycolysis in bladder cancer T24 cells via the
PTEN/PI3K/AKT/mTOR axis. Tumour Biol. 36:383–91. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang F, Li L, Chen Z, Zhu M and Gu Y:
MicroRNA-214 acts as a potential oncogene in breast cancer by
targeting the PTEN-PI3K/Akt signaling pathway. Int J Mol Med.
37:1421–1428. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Anderson KC: Progress and paradigms in
multiple myeloma. Clin Cancer Res. 22:5419–5427. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yang Z, Fang S, Di Y, Ying W, Tan Y and Gu
W: Modulation of NF-κB/miR-21/PTEN pathway sensitizes non-small
cell lung cancer to cisplatin. PLoS One. 10:e01215472015.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhang Y, Zheng L, Ding Y, Li Q, Wang R,
Liu T, Sun Q, Yang H, Peng S, Wang W and Chen L: MiR-20a induces
cell radioresistance by activating the PTEN/PI3K/Akt signaling
pathway in hepatocellular carcinoma. Int J Radiat Oncol Biol Phys.
92:1132–1140. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bates SE: Multiple myeloma: Multiplying
therapies. Clin Cancer Res. 22:54182016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wang X, Zhang H, Zhang A, Han L, Wang K,
Liu R, Yang S, Pu P, Shen C, Kang O and Yu C: Upregulation of
miR-20a and miR-106b is involved in the acquisition of malignancy
of pediatric brainstem gliomas. Oncol Rep. 28:1293–1300. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Li S, Qiang Q, Shan H, Shi M, Gan G, Ma F
and Chen B: miR-20a and miR-20b negatively regulate autophagy by
targeting RB1CC1/FIP200 in breast cancer cells. Life Sci.
147:143–152. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Gao X, Zhang R, Qu X, Zhao M, Zhang S, Wu
H, Jianyong L and Chen L: MiR-15a, miR-16-1 and miR-17-92 cluster
expression are linked to poor prognosis in multiple myeloma. Leuk
Res. 36:1505–1509. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Medema RH, Kops GJ, Bos JL and Burgering
BM: AFX-like Forkhead transcription factors mediate cell-cycle
regulation by Ras and PKB through p27kip1. Nature. 404:782–787.
2000. View
Article : Google Scholar : PubMed/NCBI
|
|
33
|
Roy SK, Srivastava RK and Shankar S:
Inhibition of PI3K/AKT and MAPK/ERK pathways causes activation of
FOXO transcription factor, leading to cell cycle arrest and
apoptosis in pancreatic cancer. J Mol Signal. 5:102010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Carnero A, Blanco-Aparicio C, Renner O,
Link W and Leal JF: The PTEN/PI3K/AKT signalling pathway in cancer,
therapeutic implications. Curr Cancer Drug Targets. 8:187–198.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Chen JS, Wang Q, Fu XH, Huang XH, Chen XL,
Cao LQ, Chen LZ, Tan HX, Li W, Bi J and Zhang LJ: Involvement of
PI3K/PTEN/AKT/mTOR pathway in invasion and metastasis in
hepatocellular carcinoma: Association with MMP-9. Hepatol Res.
39:177–186. 2009. View Article : Google Scholar : PubMed/NCBI
|
